Comparing coverage of medically indicated reduction mammoplasty among Swiss health insurers: a retrospective study.

IF 1.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Marlon Petrus, Silke Graul, Rafael Loucas, Julius M Mayer, Sebastian Leitsch, Thomas Holzbach
{"title":"Comparing coverage of medically indicated reduction mammoplasty among Swiss health insurers: a retrospective study.","authors":"Marlon Petrus, Silke Graul, Rafael Loucas, Julius M Mayer, Sebastian Leitsch, Thomas Holzbach","doi":"10.57187/s.3674","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Reduction mammoplasty is commonly used to treat macromastia, highlighting the need to address the physical and psychosocial issues associated with breast hypertrophy. However, clear inconsistencies in insurance coverage and varying criteria for medically necessary surgery are evident. The compliance of Swiss insurance companies with the 2019 recommendations of the Swiss Society of Medical Officers and Insurance Physicians has not been fully assessed.</p><p><strong>Aim: </strong>This study aimed to investigate the proportion and variability in cost approvals for reduction mammoplasty among Swiss insurers, focusing on differences in their approval and denial rates.</p><p><strong>Methods: </strong>A retrospective study was conducted on patients presenting with breast disease at Spital Thurgau AG between January 2016 and December 2022. It analysed the proportion and variability in cost approval rates for reduction mammoplasty among different insurance providers. Demographic patient data were collected and statistically analysed using chi-squared and Fisher's exact tests to evaluate if a statistically significant relationship exists between insurance providers and cost approval. Only Swiss insurance providers servicing at least five patients in the final cohort were included.</p><p><strong>Results: </strong>Between January 2016 and December 2022, 1105 patients with breast disease were evaluated at Spital Thurgau AG, of whom 210 were eligible for this study on reduction mammoplasty cost approvals. Of the 210 cost approval requests made to nine different insurance companies, 54% were approved. Approval rates differed significantly among insurers (p = 0.003).</p><p><strong>Conclusion: </strong>This study uncovered an elevated rate of cost approval denials, which depended significantly on the insurance provider. To ensure that the costs of a medically indicated breast reduction are covered consistently and fairly, a review of existing guidelines and their implementation is necessary to improve the system.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"155 ","pages":"3674"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Swiss medical weekly","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.57187/s.3674","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Reduction mammoplasty is commonly used to treat macromastia, highlighting the need to address the physical and psychosocial issues associated with breast hypertrophy. However, clear inconsistencies in insurance coverage and varying criteria for medically necessary surgery are evident. The compliance of Swiss insurance companies with the 2019 recommendations of the Swiss Society of Medical Officers and Insurance Physicians has not been fully assessed.

Aim: This study aimed to investigate the proportion and variability in cost approvals for reduction mammoplasty among Swiss insurers, focusing on differences in their approval and denial rates.

Methods: A retrospective study was conducted on patients presenting with breast disease at Spital Thurgau AG between January 2016 and December 2022. It analysed the proportion and variability in cost approval rates for reduction mammoplasty among different insurance providers. Demographic patient data were collected and statistically analysed using chi-squared and Fisher's exact tests to evaluate if a statistically significant relationship exists between insurance providers and cost approval. Only Swiss insurance providers servicing at least five patients in the final cohort were included.

Results: Between January 2016 and December 2022, 1105 patients with breast disease were evaluated at Spital Thurgau AG, of whom 210 were eligible for this study on reduction mammoplasty cost approvals. Of the 210 cost approval requests made to nine different insurance companies, 54% were approved. Approval rates differed significantly among insurers (p = 0.003).

Conclusion: This study uncovered an elevated rate of cost approval denials, which depended significantly on the insurance provider. To ensure that the costs of a medically indicated breast reduction are covered consistently and fairly, a review of existing guidelines and their implementation is necessary to improve the system.

比较瑞士健康保险公司在医学上指示的乳房缩小术的覆盖范围:一项回顾性研究。
背景:乳房缩小成形术通常用于治疗巨乳症,强调需要解决与乳房肥大相关的生理和心理问题。然而,保险范围的明显不一致和医疗上必要的手术标准的不同是显而易见的。瑞士保险公司遵守瑞士医务官员和保险医师协会2019年建议的情况尚未得到充分评估。目的:本研究旨在调查比例和变异性的成本批准减少乳房成形术在瑞士保险公司之间,重点在他们的批准和拒绝率的差异。方法:对2016年1月至2022年12月在Thurgau AG医院就诊的乳腺疾病患者进行回顾性研究。它分析了比例和变异性的成本批准率减少乳房成形术在不同的保险提供者。收集了人口统计学患者数据,并使用卡方检验和Fisher精确检验进行统计分析,以评估保险提供者与成本批准之间是否存在统计上显著的关系。在最后的队列中,只有为至少5名患者提供服务的瑞士保险公司被纳入研究。结果:2016年1月至2022年12月,在Thurgau AG医院评估了1105例乳腺疾病患者,其中210例符合降低乳房成形术成本批准的研究条件。在向9家不同的保险公司提出的210项成本批准请求中,54%获得了批准。各保险公司的批准率差异有统计学意义(p = 0.003)。结论:本研究揭示了成本批准拒绝率的升高,这与保险公司有很大关系。为了确保医学指示的缩胸手术的费用得到一致和公平的支付,有必要审查现有准则及其执行情况,以改进这一制度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Swiss medical weekly
Swiss medical weekly 医学-医学:内科
CiteScore
5.00
自引率
0.00%
发文量
0
审稿时长
3-8 weeks
期刊介绍: The Swiss Medical Weekly accepts for consideration original and review articles from all fields of medicine. The quality of SMW publications is guaranteed by a consistent policy of rigorous single-blind peer review. All editorial decisions are made by research-active academics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信